Fig. 8: Therapeutic effects of nAg-MRDE/Mn in CT-2A model and glioma PDX model. | Nature Communications

Fig. 8: Therapeutic effects of nAg-MRDE/Mn in CT-2A model and glioma PDX model.

From: Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment

Fig. 8

a Schematic diagram of the experimental design of the CT-2A model. b, c Quantitative analysis of NK cells (NK1.1+CD3+) (b) and mature DCs (CD80+CD86+) (c) in tumor. d, e Levels of IFN-γ+ T cells (CD8+IFN-γ+) (d) and GrB+ T cells (CD8+GrB+) (e) in the spleen. f, g Quantitative analysis of M2-TAMs (F4/80+CD206+) (f) and M1-TAMs (F4/80+CD86+) (g) in tumor. h Number of CD3+CD8+ T cells per mg of tumor tissue in CT-2A model mice. i Levels of Tregs (Foxp3+CD4+) in tumors. j Schematic diagram of the experimental design of the PDX model. k, l In vivo bioluminescence imaging of PDX model mice (k) and quantification of signal intensity (l). m Survival analysis of the mice. n, o Levels and representative flow cytometry plots of CD4+ T cells (CD3+CD4+) (n) and IFN-γ+ T cells (CD8+IFN-γ+) (o) in PDX model mice after different treatments. Data were mean ± SD (n = 6 mice per group). The significance between each of the multiple groups in (b–i, n, and o) was calculated using one-way ANOVA. The significance in l was calculated using two-way ANOVA. The significance in (m) was calculated using Kaplan-Meier survival analysis. Source data are provided as a Source Data file.

Back to article page